Copy number variation in archival melanoma biopsies versus benign melanocytic lesions

Society A.C. , Cancer Facts & Figures 2015. 2015: Atlanta.

Olszanski A.J. , Current and future roles of targeted therapy and immunotherapy in advanced melanoma. J Manag Care Spec Pharm, 2014. 20(4): p. 346-56.

Giblin A.V. and Thomas J.M. , Incidence, mortality and survival in cutaneous melanoma. J Plast Reconstr Aesthet Surg, 2007. 60(1): p. 32-40.

Jonsson G. , et al., Genomic profiling of malignant melanoma using tiling-resolution arrayCGH. Oncogene, 2007. 26(32): p. 4738-48.

Chin L. , Garraway L.A. , and Fisher D.E. , Malignant melanoma: Genetics and therapeutics in the genomic era. Genes Dev, 2006. 20(16): p. 2149-82.

Dabas N. , et al., Diagnostic role of chromosomal instability in melanoma. J Skin Cancer, 2012. 2012: p. 914267.

Gerami P. , et al., A highly specific and discriminatory FISH assay for distinguishing between benign and malignant melanocytic neoplasms. Am J Surg Pathol, 2012. 36(6): p. 808-17.

Corona R. , et al., Interobserver variability on the histopathologic diagnosis of cutaneous melanoma and other pigmented skin lesions. J Clin Oncol, 1996. 14(4): p. 1218-23.

Farmer E.R. , Gonin R. , and Hanna M.P. , Discordance in the histopathologic diagnosis of melanoma and melanocytic nevi between expert pathologists. Hum Pathol, 1996. 27(6): p. 528-31.

Veenhuizen K.C. , et al., Quality assessment by expert opinion in melanoma pathology: experience of the pathology panel of the Dutch Melanoma Working Party. J Pathol, 1997. 182(3): p. 266-72.

Wechsler J. , et al., Reliability of the histopathologic diagnosis of malignant melanoma in childhood. Arch Dermatol, 2002. 138(5): p. 625-8.

McGinnis K.S. , et al., Pathology review of cases presenting to a multidisciplinary pigmented lesion clinic. Arch Dermatol, 2002. 138(5): p. 617-21.

Barnhill R.L. , et al., Atypical Spitz nevi/tumors: lack of consensus for diagnosis, discrimination from melanoma, and prediction of outcome. Hum Pathol, 1999. 30(5): p. 513-20.

Lodha S. , et al., Discordance in the histopathologic diagnosis of difficult melanocytic neoplasms in the clinical setting. J Cutan Pathol, 2008. 35(4): p. 349-52.

Jing X. , Michael C.W. , and Theoharis C.G. , The use of immunocytochemical study in the cytologic diagnosis of melanoma: evaluation of three antibodies. Diagn Cytopathol, 2013. 41(2): p. 126-30.

Dorvault C.C. , et al., Microphthalmia transcription factor: a sensitive and specific marker for malignant melanoma in cytologic specimens. Cancer, 2001. 93(5): p. 337-43.

Orchard G.E. , Comparison of immunohistochemical labelling of melanocyte differentiation antibodies melan-A, tyrosinase and HMB 45 with NKIC3 and S100 protein in the evaluation of benign naevi and malignant melanoma. Histochem J, 2000. 32(8): p. 475-81.

Gerami P. , et al., Fluorescence in situ hybridization (FISH) as an ancillary diagnostic tool in the diagnosis of melanoma. Am J Surg Pathol, 2009. 33(8): p. 1146-56.

Vergier B. , et al., Fluorescence in situ hybridization, a diagnostic aid in ambiguous melanocytic tumors: European study of 113 cases. Mod Pathol, 2011. 24(5): p. 613-23.

Gaiser T. , et al., Classifying ambiguous melanocytic lesions with FISH and correlation with clinical long-term follow up. Mod Pathol, 2010. 23(3): p. 413-9.

Wang L. , et al., A genome-wide high-resolution array-CGH analysis of cutaneous melanoma and comparison of array-CGH to FISH in diagnostic evaluation. J Mol Diagn, 2013. 15(5): p. 581-91.

Kallioniemi A. , et al., Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science, 1992. 258(5083): p. 818-21.

Bastian B.C. , et al., Classifying melanocytic tumors based on DNA copy number changes. Am J Pathol, 2003. 163(5): p. 1765-70.

Bauer J. and Bastian B.C. , Distinguishing melanocytic nevi from melanoma by DNA copy number changes: comparative genomic hybridization as a research and diagnostic tool. Dermatol Ther, 2006. 19(1): p. 40-9.

Curtin J.A. , et al., Distinct sets of genetic alterations in melanoma. N Engl J Med, 2005. 353(20): p. 2135-47.

Bastian B.C. , et al., Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. Cancer Res, 1998. 58(10): p. 2170-5.

Lindblad-Toh K. , et al., Loss-of-heterozygosity analysis of small-cell lung carcinomas using single-nucleotide polymorphism arrays. Nat Biotechnol, 2000. 18(9): p. 1001-5.

Zhao X. , et al., An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays. Cancer Res, 2004. 64(9): p. 3060-71.

Bignell G.R. , et al., High-resolution analysis of DNA copy number using oligonucleotide microarrays. Genome Res, 2004. 14(2): p. 287-95.

Zhao X. , et al., Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res, 2005. 65(13): p. 5561-70.

Dalmasso C. , et al., Patterns of chromosomal copy-number alterations in intrahepatic cholangiocarcinoma. BMC Cancer, 2015. 15: p. 126.

Gast A. , et al., Somatic alterations in the melanoma genome: a high-resolution array-based comparative genomic hybridization study. Genes Chromosomes Cancer, 2010. 49(8): p. 733-45.

Stark M. and Hayward N. , Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays. Cancer Res, 2007. 67(6): p. 2632-42.

Garraway L.A. , et al., Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature, 2005. 436(7047): p. 117-22.

Kim M. , et al., Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell, 2006. 125(7): p. 1269-81.

Mermel C.H. , et al., GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol, 2011. 12(4): p. R41.

Beroukhim R. , et al., Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A, 2007. 104(50): p. 20007-12.

Beroukhim R. , et al., The landscape of somatic copy-number alteration across human cancers. Nature, 2010. 463(7283): p. 899-905.

Bass A.J. , et al., SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet, 2009. 41(11): p. 1238-42.

Chiang D.Y. , et al., Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res, 2008. 68(16): p. 6779-88.

Cancer Genome Atlas Research, N., Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature, 2008. 455(7216): p. 1061-8.

Weir B.A. , et al., Characterizing the cancer genome in lung adenocarcinoma. Nature, 2007. 450(7171): p. 893-8.

Potluri K. , et al., Genomic DNA extraction methods using formalin-fixed paraffin-embedded tissue. Anal Biochem, 2015. 486: p. 17-23.

Reich M. , et al., GenePattern 2.0. Nat Genet, 2006. 38(5): p. 500-1.

Gordon Saksena B.T. , Jeff Gentry, Broad Institute, Copy Number Inference Pipeline. 2012 [cited 2015; Available from: http://www.broadinstitute.org/cancer/software/genepa ttern/affymetrix-snp6-copy-number-inference-pipeline.

Olshen A.B. , et al., Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics, 2004. 5(4): p. 557-72.

Sullivan H.C. , et al., The utility of ERG, CD31 and CD34 in the cytological diagnosis of angiosarcoma: An analysis of 25 cases. J Clin Pathol, 2015. 68(1): p. 44-50.

Sharrocks A.D. , The ETS-domain transcription factor family. Nat Rev Mol Cell Biol, 2001. 2(11): p. 827-37.

Klezovitch O. , et al., A causal role for ERG in neoplastic transformation of prostate epithelium. Proc Natl Acad Sci U S A, 2008. 105(6): p. 2105-10.

Furusato B. , et al., ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification. Prostate Cancer Prostatic Dis, 2010. 13(3): p. 228-37.

Falzarano S.M. and Magi-Galluzzi C. , ERG protein expression as a biomarker of prostate cancer. Biomark Med, 2013. 7(6): p. 851-65.

Zong Y. , et al., ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells. Proc Natl Acad Sci U S A, 2009. 106(30): p. 12465-70.

Minner S. , et al., High level of Ets-related gene expression has high specificity for prostate cancer: a tissue microarray study of 11 483 cancers. Histopathology, 2012. 61(3): p. 445-53.

Zhu J. , et al., Guanylate kinase domains of the MAGUK family scaffold proteins as specific phospho-protein-binding modules. EMBO J, 2011. 30(24): p. 4986-97.

Zubakov D. , Stupar Z. , and Kovacs G. , Differential expression of a new isoform of DLG2 in renal oncocytoma. BMC Cancer, 2006. 6: p. 106.

Morandi A. , Plaza-Menacho I. , and Isacke C.M. , RET in breast cancer: functional and therapeutic implications. Trends Mol Med, 2011. 17(3): p. 149-57.

Santoro M. , et al., Molecular mechanisms of RET activation in human cancer. Ann N Y Acad Sci, 2002. 963: p. 116-21.

Jhiang S.M. , The RET proto-oncogene in human cancers. Oncogene, 2000. 19(49): p. 5590-7.

Nakashima M. , et al., RET oncogene amplification in thyroid cancer: correlations with radiation-associated and high-grade malignancy. Hum Pathol, 2007. 38(4): p. 621-8.

Yang H.S. and Horten B. , Gain of copy number and amplification of the RET gene in lung cancer. Exp Mol Pathol, 2014. 97(3): p. 465-9.

Zeng Q. , et al., The relationship between overexpression of glial cell-derived neurotrophic factor and its RET receptor with progression and prognosis of human pancreatic cancer. J Int Med Res, 2008. 36(4): p. 656-64.

Narita N. , et al., Functional RET G691S polymorphism in cutaneous malignant melanoma. Oncogene, 2009. 28(34): p. 3058-68.

Ohshima Y. , et al., c-RET molecule in malignant melanoma from oncogenic RET-carrying transgenic mice and human cell lines. PLoS One, 2010. 5(4): p. e10279.

Santos G.C. , et al., Chromosome 6p amplification and cancer progression. J Clin Pathol, 2007. 60(1): p. 1-7.

Khodadoust M.S. , et al., Melanoma proliferation and chemoresistance controlled by the DEK oncogene. Cancer Res, 2009. 69(16): p. 6405-13.

Feber A. , et al., Amplification and overexpression of E2F3 in human bladder cancer. Oncogene, 2004. 23(8): p. 1627-30.

Namiki T. , et al., Genomic alterations in primary cutaneous melanomas detected by metaphase comparative genomic hybridization with laser capture or manual microdissection: 6p gains may predict poor outcome. Cancer Genet Cytogenet, 2005. 157(1): p. 1-11.

Robertson G.P. , Functional and therapeutic significance of Akt deregulation in malignant melanoma. Cancer Metastasis Rev, 2005. 24(2): p. 273-85.

Stahl J.M. , et al., Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res, 2004. 64(19): p. 7002-10.

Gembarska A. , et al., MDM4 is a key therapeutic target in cutaneous melanoma. Nat Med, 2012. 18(8): p. 1239-47.

Ganguly S.S. , et al., c-Abl and Arg are activated in human primary melanomas, promote melanoma cell invasion via distinct pathways, and drive metastatic progression. Oncogene, 2012. 31(14): p. 1804-16.

van den Bosch T. , et al., Higher percentage of FISH-determined monosomy 3 and 8q amplification in uveal melanoma cells relate to poor patient prognosis. Invest Ophthalmol Vis Sci, 2012. 53(6): p. 2668-74.

Gerami P. , et al., Copy number gains in 11q13 and 8q24 [corrected] are highly linked to prognosis in cutaneous malignant melanoma. J Mol Diagn, 2011. 13(3): p. 352-8.

Chen Y. and Olopade O.I. , MYC in breast tumor progression. Expert Rev Anticancer Ther, 2008. 8(10): p. 1689-98.

Jenkins R.B. , et al., Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res, 1997. 57(3): p. 524-31.

Singhi A.D. , et al., MYC gene amplification is often acquired in lethal distant breast cancer metastases of unamplified primary tumors. Mod Pathol, 2012. 25(3): p. 378-87.

Pouryazdanparast P. , et al., The role of 8q24 copy number gains and c-MYC expression in amelanotic cutaneous melanoma. Mod Pathol, 2012. 25(9): p. 1221-6.

Jane-Valbuena J. , et al., An oncogenic role for ETV1 in melanoma. Cancer Res, 2010. 70(5): p. 2075-84.

Davies H. , et al., Mutations of the BRAF gene in human cancer. Nature, 2002. 417(6892): p. 949-54.

Holzmann K. , et al., Genomic DNA-chip hybridization reveals a higher incidence of genomic amplifications in pancreatic cancer than conventional comparative genomic hybridization and leads to the identification of novel candidate genes. Cancer Res, 2004. 64(13): p. 4428-33.

Liang J.W. , et al., Analysis of genomic aberrations associated with the clinicopathological parameters of rectal cancer by arraybased comparative genomic hybridization. Oncol Rep, 2013. 29(5): p. 1827-34.

Papaemmanuil E. , et al., Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia. Nat Genet, 2009. 41(9): p. 1006-10.

Hulsebos T.J. , et al., Malignant astrocytoma-derived region of common amplification in chromosomal band 17p12 is frequently amplified in high-grade osteosarcomas. Genes Chromosomes Cancer, 1997. 18(4): p. 279-85.

Wang Y. , Minoshima S. , and Shimizu N. , Precise mapping of the EGF receptor gene on the human chromosome 7p12 using an improved fish technique. Jpn J Hum Genet, 1993. 38(4): p. 399-406.

Yarden Y. and Pines G. , The ERBB network: at last, cancer therapy meets systems biology. Nat Rev Cancer, 2012. 12(8): p. 553-63.

Kang J.U. , et al., Gain of the EGFR gene located on 7p12 is a frequent and early event in squamous cell carcinoma of the lung. Cancer Genet Cytogenet, 2008. 184(1): p. 31-7.

Higaki E. , et al., Gene copy number gain of EGFR is a poor prognostic biomarker in gastric cancer: evaluation of 855 patients with bright-field dual in situ hybridization (DISH) method. Gastric Cancer, 2014.

Moore S.R. , et al., Detection of copy number alterations in metastatic melanoma by a DNA fluorescence in situ hybridization probe panel and array comparative genomic hybridization: a southwest oncology group study (S9431). Clin Cancer Res, 2008. 14(10): p. 2927-35.

Udart M. , et al., Chromosome 7 aneusomy. A marker for metastatic melanoma? Expression of the epidermal growth factor receptor gene and chromosome 7 aneusomy in nevi, primary malignant melanomas and metastases. Neoplasia, 2001. 3(3): p. 245-54.

Koprowski H. , et al., Expression of the receptor for epidermal growth factor correlates with increased dosage of chromosome 7 in malignant melanoma. Somat Cell Mol Genet, 1985. 11(3): p. 297-302.

Pulkkinen V. , et al., Neuropeptide S receptor 1 (NPSR1) activates cancer-related pathways and is widely expressed in neuroendocrine tumors. Virchows Arch, 2014. 465(2): p. 173-83.

Huang S.F. , et al., Fluorescence in situ hybridization evaluation of chromosome deletion patterns in prostate cancer. Am J Pathol, 1996. 149(5): p. 1565-73.

Armes J.E. , et al., Candidate tumor-suppressor genes on chromosome arm 8p in early-onset and high-grade breast cancers. Oncogene, 2004. 23(33): p. 5697-702.

Zhang R. and Song C. , Loss of CSMD1 or 2 may contribute to the poor prognosis of colorectal cancer patients. Tumour Biol, 2014. 35(5): p. 4419-23.

Midorikawa Y. , et al., Allelic imbalances and homozygous deletion on 8p23.2 for stepwise progression of hepatocarcinogenesis. Hepatology, 2009. 49(2): p. 513-22.

Wright K. , et al., Frequent loss of heterozygosity and three critical regions on the short arm of chromosome 8 in ovarian adenocarcinomas. Oncogene, 1998. 17(9): p. 1185-8.

Ma C. , et al., Characterization CSMD1 in a large set of primary lung, head and neck, breast and skin cancer tissues. Cancer Biol Ther, 2009. 8(10): p. 907-16.

Sun P.C. , et al., Transcript map of the 8p23 putative tumor suppressor region. Genomics, 2001. 75(1-3): p. 17-25.

Tang M.R. , et al., CSMD1 exhibits antitumor activity in A375 melanoma cells through activation of the Smad pathway. Apoptosis, 2012. 17(9): p. 927-37.

Turner N.C. and Reis-Filho J.S. , Basal-like breast cancer and the BRCA1 phenotype. Oncogene, 2006. 25(43): p. 5846-53.

Brosens R.P. , et al., Deletion of chromosome 4q predicts outcome in stage II colon cancer patients. Cell Oncol (Dordr), 2011. 34(3): p. 215-23.

Kimura Y. , et al., Genetic alterations in 102 primary gastric cancers by comparative genomic hybridization: gain of 20q and loss of 18q are associated with tumor progression. Mod Pathol, 2004. 17(11): p. 1328-37.

Han J.Y. , et al., Whole-genome analysis of a patient with early-stage small-cell lung cancer. Pharmacogenomics J, 2014. 14(6): p. 503-8.

di Martino E. , et al., An integrated genomic, transcriptional and protein investigation of FGFRL1 as a putative 4p16.3 deletion target in bladder cancer. Genes Chromosomes Cancer, 2013. 52(9): p. 860-71.

Schild C. and Trueb B. , Aberrant expression of FGFRL1, a novel FGF receptor, in ovarian tumors. Int J Mol Med, 2005. 16(6): p. 1169-73.

Xu L. , et al., An emerging role of PARK2 in cancer. J Mol Med (Berl), 2014. 92(1): p. 31-42.

Gong Y. , et al., Pan-cancer genetic analysis identifies PARK2 as a master regulator of G1/S cyclins. Nat Genet, 2014. 46(6): p. 588-94.

Toma M.I. , et al., PARK2 and PACRG are commonly downregulated in clear-cell renal cell carcinoma and are associated with aggressive disease and poor clinical outcome. Genes Chromosomes Cancer, 2013. 52(3): p. 265-73.

Goldberg E.K. , et al., Localization of multiple melanoma tumor-suppressor genes on chromosome 11 by use of homozygosity mapping-of-deletions analysis. Am J Hum Genet, 2000. 67(2): p. 417-31.

Tomlinson I.P. , et al., Loss of heterozygosity on chromosome 11 q in breast cancer. J Clin Pathol, 1995. 48(5): p. 424-8.

Walch A.K. , et al., Typical and atypical carcinoid tumors of the lung are characterized by 11q deletions as detected by comparative genomic hybridization. Am J Pathol, 1998. 153(4): p. 1089-98.

Spitz R. , et al., Deletions in chromosome arms 3p and 11q are new prognostic markers in localized and 4s neuroblastoma. Clin Cancer Res, 2003. 9(1): p. 52-8.

Sun X.X. and Dai M.S. , Deubiquitinating enzyme regulation of the p53 pathway: A lesson from Otub1. World J Biol Chem, 2014. 5(2): p. 75-84.

Sun X.X. , Challagundla K.B. , and Dai M.S. , Positive regulation of p53 stability and activity by the deubiquitinating enzyme Otubain 1. EMBO J, 2012. 31(3): p. 576-92.

Imuta Y. , et al., Short limbs, cleft palate, and delayed formation of flat proliferative chondrocytes in mice with targeted disruption of a putative protein kinase gene, Pkdcc (AW548124). Dev Dyn, 2009. 238(1): p. 210-22.

Martelli M.P. , et al., EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. Am J Pathol, 2009. 174(2): p. 661-70.

Fukuyoshi Y. , et al., EML4-ALK fusion transcript is not found in gastrointestinal and breast cancers. Br J Cancer, 2008. 98(9): p. 1536-9.

Penzel R. , Schirmacher P. , and Warth A. , A novel EML4-ALK variant: exon 6 of EML4 fused to exon 19 of ALK. J Thorac Oncol, 2012. 7(7): p. 1198-9.

Soda M. , et al., Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature, 2007. 448(7153): p. 561-6.

Sanz L. , et al., The interaction of p62 with RIP links the atypical PKCs to NF-kappaB activation. EMBO J, 1999. 18(11): p. 3044-53.

Hoesel B. and Schmid J.A. , The complexity of NF-kappaB signaling in inflammation and cancer. Mol Cancer, 2013. 12: p. 86.

Mendes-da-Silva P. , et al., Frequent loss of heterozygosity on chromosome 5 in non-small cell lung carcinoma. Mol Pathol, 2000. 53(4): p. 184-7.

Johannsdottir H.K. , et al., Chromosome 5 imbalance mapping in breast tumors from BRCA1 and BRCA2 mutation carriers and sporadic breast tumors. Int J Cancer, 2006. 119(5): p. 1052-60.

Piao Z. , et al., Identification of novel deletion regions on chromosome arms 2q and 6p in breast carcinomas by amplotype analysis. Genes Chromosomes Cancer, 2001. 30(2): p. 113-22.

Mazurenko N. , et al., High resolution mapping of chromosome 6 deletions in cervical cancer. Oncol Rep, 1999. 6(4): p. 859-63.

Zudaire E. , et al., The aryl hydrocarbon receptor repressor is a putative tumor suppressor gene in multiple human cancers. J Clin Invest, 2008. 118(2): p. 640-50.

Lu Y. , et al., Identification of a new target region by loss of heterozygosity at 5p15.33 in sporadic gastric carcinomas: genotype and phenotype related. Cancer Lett, 2005. 224(2): p. 329-37.

Xu S.F. , et al., Refinement of heterozygosity loss on chromosome 5p15 in sporadic colorectal cancer. World J Gastroenterol, 2003. 9(8): p. 1713-8.

Arias-Pulido H. , et al., Mapping common deleted regions on 5p15 in cervical carcinoma and their occurrence in precancerous lesions. Mol Cancer, 2002. 1: p. 3.

Burnichon N. , et al., SDHA is a tumor suppressor gene causing paraganglioma. Hum Mol Genet, 2010. 19(15): p. 3011-20.

Zhao S. , et al., NKD2, a negative regulator of Wnt signaling, suppresses tumor growth and metastasis in osteosarcoma. Oncogene, 2015.

Burger H. , et al., Chromosome 16q loss-a genetic key to the understanding of breast carcinogenesis. Histol Histopathol, 2013. 28(3): p. 311-20.

Yakicier M.C. , et al., Identification of homozygous deletions at chromosome 16q23 in aflatoxin B1 exposed hepatocellular carcinoma. Oncogene, 2001. 20(37): p. 5232-8.

Li C. , et al., Distinct deleted regions on chromosome segment 16q23-24 associated with metastases in prostate cancer. Genes Chromosomes Cancer, 1999. 24(3): p. 175-82.

Vincek V. , Xu S. , and Fan Y.S. , Comparative genome hybridization analysis of laser-capture microdissected in situ melanoma. J Cutan Pathol, 2010. 37(1): p. 3-7.

Balazs M. , et al., Chromosomal imbalances in primary and metastatic melanomas revealed by comparative genomic hybridization. Cytometry, 2001. 46(4): p. 222-32.

Andreeva A.V. and Kutuzov M.A. , Cadherin 13 in cancer. Genes Chromosomes Cancer, 2010. 49(9): p. 775-90.

Andersen L.B. , et al., Mutations in the neurofibromatosis 1 gene in sporadic malignant melanoma cell lines. Nat Genet, 1993. 3(2): p. 118-21.

Nissan M.H. , et al., Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence. Cancer Res, 2014. 74(8): p. 2340-50.

Johnson M.R. , et al., Inactivation of the NF1 gene in human melanoma and neuroblastoma cell lines without impaired regulation of GTP.Ras. Proc Natl Acad Sci U S A, 1993. 90(12): p. 5539-43.

Krauthammer M. , et al., Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas. Nat Genet, 2015.

North J.P. , Vemula S.S. , and Bastian B.C. , Chromosomal copy number analysis in melanoma diagnostics. Methods Mol Biol, 2014. 1102: p. 199-226.

Song L. , et al., Alteration of SMRT tumor suppressor function in transformed non-Hodgkin lymphomas. Cancer Res, 2005. 65(11): p. 4554-61.

Ghoshal P. , et al., Loss of the SMRT/NCoR2 corepressor correlates with JAG2 overexpression in multiple myeloma. Cancer Res, 2009. 69(10): p. 4380-7.

Adikesavan A.K. , et al., Activation of p53 transcriptional activity by SMRT: a histone deacetylase 3-independent function of a transcriptional corepressor. Mol Cell Biol, 2014. 34(7): p. 1246-61.

Yang Y. , et al., LPLUNC1 inhibits nasopharyngeal carcinoma cell growth via down-regulation of the MAP kinase and cyclin D1/E2F pathways. PLoS One, 2013. 8(5): p. e62869.

Liao Q. , et al., LPLUNC1 suppresses IL-6-induced nasopharyngeal carcinoma cell proliferation via inhibiting the Stat3 activation. Oncogene, 2014. 33(16): p. 2098-109.

Majid S.M. , et al., The suppression of SH3BGRL is important for v-Rel-mediated transformation. Oncogene, 2006. 25(5): p. 756-68.

Dankort D. , et al., Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet, 2009. 41(5): p. 544-52.

Lin W.M. , et al., Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res, 2008. 68(3): p. 664-73.

Peters J.M. and Nishiyama T. , Sister chromatid cohesion. Cold Spring Harb Perspect Biol, 2012. 4(11).

Peters J.M. , Tedeschi A. , and Schmitz J. , The cohesin complex and its roles in chromosome biology. Genes Dev, 2008. 22(22): p. 3089-114.

Girard L. , et al., Genome-wide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non-small cell lung cancer, and loci clustering. Cancer Res, 2000. 60(17): p. 4894-906.

Shin J.H. , et al., Identification of tumor suppressor loci on the long arm of chromosome 5 in pulmonary large cell neuroendocrine carcinoma. Chest, 2005. 128(4): p. 2999-3003.

Treszl A. , et al., Molecular cytogenetic characterization of a novel cell line established from a superficial spreading melanoma. Front Biosci, 2006. 11: p. 1844-53.

Noutsou M. , et al., Critical scaffolding regions of the tumor suppressor Axin1 are natively unfolded. J Mol Biol, 2011. 405(3): p. 773-86.

Salahshor S. and Woodgett J.R. , The links between axin and carcinogenesis. J Clin Pathol, 2005. 58(3): p. 225-36.

Rui Y. , et al., Axin stimulates p53 functions by activation of HIPK2 kinase through multimeric complex formation. EMBO J, 2004. 23(23): p. 4583-94.

Wang P. , et al., GM3 signals regulating TNF-alpha expression are mediated by Rictor and Arhgdib in mouse melanoma B16 cells. Oncology, 2007. 73(5-6): p. 430-8.

Morelle A. , et al., Clinical and genetic characterization of basal cell carcinoma and breast cancer in a single patient. Springerplus, 2014. 3: p. 454.

Rouault A. , et al., Deletion of chromosomes 13q and 14q is a common feature of tumors with BRCA2 mutations. PLoS One, 2012. 7(12): p. e52079.

Lo F.Y. , et al., The database of chromosome imbalance regions and genes resided in lung cancer from Asian and Caucasian identified by array-comparative genomic hybridization. BMC Cancer, 2012. 12: p. 235.

LeBron C. , et al., Genome-wide analysis of genetic alterations in testicular primary seminoma using high resolution single nucleotide polymorphism arrays. Genomics, 2011. 97(6): p. 341-9.

Niini T. , et al., Array comparative genomic hybridization reveals frequent alterations of G1/S checkpoint genes in undifferentiated pleomorphic sarcoma of bone. Genes Chromosomes Cancer, 2011. 50(5): p. 291-306.

Liu X. , et al., Zinc finger protein ZBTB20 promotes Toll-like receptor-triggered innate immune responses by repressing IkappaBalpha gene transcription. Proc Natl Acad Sci U S A, 2013. 110(27): p. 11097-102.

Zhou G. , et al., Zbtb20 regulates the terminal differentiation of hypertrophic chondrocytes via repression of Sox9. Development, 2015. 142(2): p. 385-93.

Shakhova O. , et al., Antagonistic cross-regulation between Sox9 and Sox10 controls an anti-tumorigenic program in melanoma. PLoS Genet, 2015. 11(1): p. e1004877.

Nakao M. , et al., DNA copy number aberrations associated with the clinicopathological features of colorectal cancers: Identification of genomic biomarkers by array-based comparative genomic hybridization. Oncol Rep, 2011. 25(6): p. 1603-11.

Kwong L.N. and Chin L. , Chromosome 10, frequently lost in human melanoma, encodes multiple tumor-suppressive functions. Cancer Res, 2014. 74(6): p. 1814-21.

Paz N. , et al., Altered adenosine-to-inosine RNA editing in human cancer. Genome Res, 2007. 17(11): p. 1586-95.

Yendamuri S. , et al., 3p22.1 and 10q22.3 deletions detected by fluorescence in situ hybridization (FISH): a potential new tool for early detection of non-small cell lung Cancer (NSCLC). J Thorac Oncol, 2008. 3(9): p. 979-84.

Mlakar V. , et al., Oligonucleotide DNA microarray profiling of lung adenocarcinoma revealed significant downregulation and deletions of vasoactive intestinal peptide receptor 1. Cancer Invest, 2010. 28(5): p. 487-94.

Reinert T. , et al., Comprehensive genome methylation analysis in bladder cancer: identification and validation of novel methylated genes and application of these as urinary tumor markers. Clin Cancer Res, 2011. 17(17): p. 5582-92.

Chen L. , et al., Clonality and evolutionary history of rhabdomyosarcoma. PLoS Genet, 2015. 11(3): p. e1005075.

Soon P.S. , et al., Molecular markers and the pathogenesis of adrenocortical cancer. Oncologist, 2008. 13(5): p. 548-61.

Czarnecka K.H. , et al., Allelic imbalance in 1p, 7q, 9p, 11p, 12q and 16q regions in non-small cell lung carcinoma and its clinical association: a pilot study. Mol Biol Rep, 2013. 40(12): p. 6671-84.

Kim S.W. , et al., Analysis of chromosomal changes in serous ovarian carcinoma using high-resolution array comparative genomic hybridization: Potential predictive markers of chemoresistant disease. Genes Chromosomes Cancer, 2007. 46(1): p. 1-9.

Wikman H. , et al., Clinical relevance of loss of 11p15 in primary and metastatic breast cancer: association with loss of PRKCDBP expression in brain metastases. PLoS One, 2012. 7(10): p. e47537.

Chiu C.G. , et al., Genome-wide characterization of circulating tumor cells identifies novel prognostic genomic alterations in systemic melanoma metastasis. Clin Chem, 2014. 60(6): p. 873-85.

Orfanelli U. , et al., Identification of novel sense and antisense transcription at the TRPM2 locus in cancer. Cell Res, 2008. 18(11): p. 1128-40.

Duncan L.M. , et al., Down-regulation of the novel gene melastatin correlates with potential for melanoma metastasis. Cancer Res, 1998. 58(7): p. 1515-20.

Boyd L.K. , et al., High-resolution genome-wide copy-number analysis suggests a monoclonal origin of multifocal prostate cancer. Genes Chromosomes Cancer, 2012. 51(6): p. 579-89.

Januchowski R. , et al., Extracellular matrix proteins expression profiling in chemoresistant variants of the A2780 ovarian cancer cell line. Biomed Res Int, 2014. 2014: p. 365867.

Vincent A. , et al., Genome-wide analysis of promoter methylation associated with gene expression profile in pancreatic adenocarcinoma. Clin Cancer Res, 2011. 17(13): p. 4341-54.

Potier M. , et al., Identification of SK3 channel as a new mediator of breast cancer cell migration. Mol Cancer Ther, 2006. 5(11): p. 2946-53.

Chantome A. , et al., KCa2.3 channel-dependent hyperpolarization increases melanoma cell motility. Exp Cell Res, 2009. 315(20): p. 3620-30.

Sun W. , et al., PPM1A and PPM1B act as IKKbeta phosphatases to terminate TNFalpha-induced IKKbeta-NF-kappaB activation. Cell Signal, 2009. 21(1): p. 95-102.

Hayward N.K. , Genetics of melanoma predisposition. Oncogene, 2003. 22(20): p. 3053-62.

Marzuka-Alcala A. , Gabree M.J. , and Tsao H. , Melanoma susceptibility genes and risk assessment. Methods Mol Biol, 2014. 1102: p. 381-93.

Young R.J. , et al., Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines. Pigment Cell Melanoma Res, 2014. 27(4): p. 590-600.

Hodis E. , et al., A landscape of driver mutations in melanoma. Cell, 2012. 150(2): p. 251-63.

Frigerio S. , et al., A large de novo 9p21.3 deletion in a girl affected by astrocytoma and multiple melanoma. BMC Med Genet, 2014. 15: p. 59.

Laharanne E. , et al., CDKN2A-CDKN2B deletion defines an aggressive subset of cutaneous T-cell lymphoma. Mod Pathol, 2010. 23(4): p. 547-58.

Kamath A. , et al., Double-minute MYC amplification and deletion of MTAP, CDKN2A, CDKN2B, and ELAVL2 in an acute myeloid leukemia characterized by oligonucleotide-array comparative genomic hybridization. Cancer Genet Cytogenet, 2008. 183(2): p. 117-20.

Mirebeau D. , et al., The prognostic significance of CDKN2A, CDKN2B and MTAP inactivation in B-lineage acute lymphoblastic leukemia of childhood. Results of the EORTC studies 58881 and 58951. Haematologica, 2006. 91(7): p. 881-5.

Worsham M.J. , et al., Fine-mapping loss of gene architecture at the CDKN2B (p15INK4b), CDKN2A (p14ARF, p16INK4a), and MTAP genes in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg, 2006. 132(4): p. 409-15.

Illei P.B. , et al., Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas. Clin Cancer Res, 2003. 9(6): p. 2108-13.

Crespo I. , et al., Detailed characterization of alterations of chromosomes 7, 9, and 10 in glioblastomas as assessed by single-nucleotide polymorphism arrays. J Mol Diagn, 2011. 13(6): p. 634-47.

Kohno T. and Yokota J. , Molecular processes of chromosome 9p21 deletions causing inactivation of the p16 tumor suppressor gene in human cancer: deduction from structural analysis of breakpoints for deletions. DNA Repair (Amst), 2006. 5(9-10): p. 1273-81.

Sasaki S. , et al., Molecular processes of chromosome 9p21 deletions in human cancers. Oncogene, 2003. 22(24): p. 3792-8.

Busam K.J. , Molecular pathology of melanocytic tumors. Semin Diagn Pathol, 2013. 30(4): p. 362-74.

Shahbain H. , Cooper C. , and Gerami P. , Molecular diagnostics for ambiguous melanocytic tumors. Semin Cutan Med Surg, 2012. 31(4): p. 274-8.

Johnstone C.N. , et al., PRR5 encodes a conserved proline-rich protein predominant in kidney: analysis of genomic organization, expression, and mutation status in breast and colorectal carcinomas. Genomics, 2005. 85(3): p. 338-51.

Chinnadurai G. , Vijayalingam S. , and Rashmi R. , BIK, the founding member of the BH3-only family proteins: mechanisms of cell death and role in cancer and pathogenic processes. Oncogene, 2008. 27 Suppl 1: p. S20-9.

Oppermann M. , et al., Caspase-independent induction of apoptosis in human melanoma cells by the proapoptotic Bcl-2-related protein Nbk/Bik. Oncogene, 2005. 24(49): p. 7369-80.

Lai C.P. , Bechberger J.F. , and Naus C.C. , Pannexin2 as a novel growth regulator in C6 glioma cells. Oncogene, 2009. 28(49): p. 4402-8.

Cowan K.N. , et al., Pannexin1 and Pannexin3 exhibit distinct localization patterns in human skin appendages and are regulated during keratinocyte differentiation and carcinogenesis. Cell Commun Adhes, 2012. 19(3-4): p. 45-53.

Penuela S. , et al., Loss of pannexin 1 attenuates melanoma progression by reversion to a melanocytic phenotype. J Biol Chem, 2012. 287(34): p. 29184-93.

Cornella H. , et al., Unique genomic profile of fibrolamellar hepatocellular carcinoma. Gastroenterology, 2015. 148(4): p. 806-818 e10.

Fulda S. , Caspase-8 in cancer biology and therapy. Cancer Lett, 2009. 281(2): p. 128-33.

Park W.S. , et al., Inactivating mutations of the caspase-10 gene in gastric cancer. Oncogene, 2002. 21(18): p. 2919-25.

Shin M.S. , et al., Inactivating mutations of CASP10 gene in non-Hodgkin lymphomas. Blood, 2002. 99(11): p. 4094-9.

Yamamoto N. , et al., Allelic loss on chromosomes 2q, 3p and 21q: possibly a poor prognostic factor in oral squamous cell carcinoma. Oral Oncol, 2003. 39(8): p. 796-805.

Beder L.B. , et al., Genome-wide analyses on loss of heterozygosity in head and neck squamous cell carcinomas. Lab Invest, 2003. 83(1): p. 99-105.

Pack S.D. , et al., Molecular cytogenetic fingerprinting of esophageal squamous cell carcinoma by comparative genomic hybridization reveals a consistent pattern of chromosomal alterations. Genes Chromosomes Cancer, 1999. 25(2): p. 160-8.

Otsuka T. , et al., Deletion mapping of chromosome 2 in human lung carcinoma. Genes Chromosomes Cancer, 1996. 16(2): p. 113-9.

Takita J. , et al., Allelic imbalance on chromosome 2q and alterations of the caspase 8 gene in neuroblastoma. Oncogene, 2001. 20(32): p. 4424-32.

Dahl E. , et al., Systematic identification and molecular characterization of genes differentially expressed in breast and ovarian cancer. J Pathol, 2005. 205(1): p. 21-8.

Huang C. , Roles of E3 ubiquitin ligases in cell adhesion and migration. Cell Adh Migr, 2010. 4(1): p. 10-8.

Kano S. , et al., Tripartite motif protein 32 facilitates cell growth and migration via degradation of Abl-interactor 2. Cancer Res, 2008. 68(14): p. 5572-80.

Szuhai K. , et al., Array-CGH analysis of cutaneous anaplastic large cell lymphoma. Methods Mol Biol, 2013. 973: p. 197-212.

Gelmez M.Y. , et al., Analysis of activation-induced cytidine deaminase mRNA levels in patients with chronic lymphocytic leukemia with different cytogenetic status. Leuk Lymphoma, 2014. 55(2): p. 326-30.

Nelson M. , et al., An increased frequency of 13q deletions detected by fluorescence in situ hybridization and its impact on survival in children and adolescents with Burkitt lymphoma: results from the Children's Oncology Group study CCG-5961. Br J Haematol, 2010. 148(4): p. 600-10.

Oh E.K. , et al., Differential DNA copy number aberrations in the progression of cervical lesions to invasive cervical carcinoma. Int J Oncol, 2012. 41(6): p. 2038-46.

Son J.W. , et al., Genome-wide combination profiling of DNA copy number and methylation for deciphering biomarkers in non-small cell lung cancer patients. Cancer Lett, 2011. 311(1): p. 29-37.

Laharanne E. , et al., Genome-wide analysis of cutaneous T-cell lymphomas identifies three clinically relevant classes. J Invest Dermatol, 2010. 130(6): p. 1707-18.

Gao Y. , et al., Chromosome aberrations associated with centrosome defects: a study of comparative genomic hybridization in breast cancer. Hum Pathol, 2011. 42(11): p. 1693-701.

Antic D. , et al., Monosomy 12 and deletion of 13q34 in a case of chronic lymphocytic leukemia with concomitant lung cancer. Vojnosanit Pregl, 2010. 67(10): p. 864-6.

Chattopadhyay I. , et al., Genome-wide analysis of chromosomal alterations in patients with esophageal squamous cell carcinoma exposed to tobacco and betel quid from high-risk area in India. Mutat Res, 2010. 696(2): p. 130-8.

Igci M. , et al., Loss of heterozygosity of chromosome 13q33-34 region and molecular analysis of ING1 and p53 genes in bladder carcinoma. Mol Biol Rep, 2015. 42(2): p. 507-16.

Garkavtsev I. , et al., Suppression of the novel growth inhibitor p33ING1 promotes neoplastic transformation. Nat Genet, 1996. 14(4): p. 415-20.

Guerillon C. , Bigot N. , and Pedeux R. , The ING tumor suppressor genes: status in human tumors. Cancer Lett, 2014. 345(1): p. 1-16.

Luo Z.G. , et al., Genetic alterations of tumor suppressor ING1 in human non-small cell lung cancer. Oncol Rep, 2011. 25(4): p. 1073-81.

Wei S.C. , et al., SLCO3A1, A novel crohn's disease-associated gene, regulates nf-kappaB activity and associates with intestinal perforation. PLoS One, 2014. 9(6): p. e100515.

Hays A. , Apte U. , and Hagenbuch B. , Organic anion transporting polypeptides expressed in pancreatic cancer may serve as potential diagnostic markers and therapeutic targets for early stage adenocarcinomas. Pharm Res, 2013. 30(9): p. 2260-9.

Giguere A. and J. Hebert , Identification of a novel fusion gene involving RUNX1 and the antisense strand of SV2B in a BCR-ABL1-positive acute leukemia. Genes Chromosomes Cancer, 2013. 52(12): p. 1114-22.

Hoglund M. , The bladder cancer genome; chromosomal changes as prognostic makers, opportunities, and obstacles. Urol Oncol, 2012. 30(4): p. 533-40.

Williams S.V. , et al., Molecular genetic analysis of chromosome 9 candidate tumor-suppressor loci in bladder cancer cell lines. Genes Chromosomes Cancer, 34(1): p. 86-96.

Isshiki K. , et al., Chromosome 9 deletion in sporadic and familial melanomas in vivo. Oncogene, 1994. 9(6): p. 1649-53.

Moore D.A. , et al., Duplex Ratio Tests as Diagnostic Biomarkers in Malignant Melanoma. J Mol Diagn, 2015. 17(5): p. 616-22.

Lanzi C. , et al., Targeting RET for thyroid cancer therapy. Biochem Pharmacol, 2009. 77(3): p. 297-309.

Mazumdar M. , et al., Targeting RET to induce medullary thyroid cancer cell apoptosis: an antagonistic interplay between PI3K/Akt and p38MAPK/caspase-8 pathways. Apoptosis, 2013. 18(5): p. 589-604.

Phay J.E. and Shah M.H. , Targeting RET receptor tyrosine kinase activation in cancer. Clin Cancer Res, 2010. 16(24): p. 5936-41.

Kissick H.T. , et al., Development of a peptide-based vaccine targeting TMPRSS2:ERG fusion-positive prostate cancer. Cancer Immunol Immunother, 2013. 62(12): p. 1831-40.

Nhili R. , et al., Targeting the DNA-binding activity of the human ERG transcription factor using new heterocyclic dithiophene diamidines. Nucleic Acids Res, 2013. 41(1): p. 125-38.